XXth Congress of the European Society of Cardiology. Satellite Symposia. Vienna, ATR, 1998/08.
Alms To compare resource consumption and medical costs between patients with unstable angina and non-Q wave myocardial infarction randomized to eptifibatide or placebo in the Western European arm of the PURSUIT (Platelet GP IIb/IIIa in Unstable Angina : Receptor Suppression Using Integrilin Therapy) Trial.
Methods and Results The PURSUIT trial collected medical resource consumption data for enrolled patients.
Analyses of resources consumed were conducted for the 3697 patients recruited in Western Europe and for subgroups with different coronary arteriography rates.
Unit costs were developed for six Western European countries using consistent bottom-up costing methods.
These costs were applied to the resource consumption to estimate the medical treatment costs for patients assigned eptifibatide or placebo.
Resource consumption varied across the six countries with a trend for lower rates of coronary arteriography and myocardial revascularization amongst eptifibatide patients.
The mean costs of the initial hospital admission, including 526 EUROs for eptifibatide treatment, were 1.1% to 6.8% higher than placebo.
The incremental costs associated with eptifibatide patients enrolled in the low and medium coronary arteriography rate countries were lower than those observed in high coronary arteriography rate countries. (...)
Mots-clés Pascal : Angor instable, Eptifibatide, Europe Ouest, Europe, Analyse coût, Economie santé, Chimiothérapie, Traitement, Homme, Etude comparative, Inhibiteur thromboagrégation, Appareil circulatoire pathologie, Cardiopathie coronaire
Mots-clés Pascal anglais : Variant angina, Eptifibatide, Western Europe, Europe, Cost analysis, Health economy, Chemotherapy, Treatment, Human, Comparative study, Antiplatelet agent, Cardiovascular disease, Coronary heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0475270
Code Inist : 002B02G. Création : 22/03/2000.